Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07701993
PHASE3

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Sponsor: GlaxoSmithKline

View on ClinicalTrials.gov

Summary

This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.

Official title: A Phase 3, Double-blind, Randomized, Placebo Controlled, 2-arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-1)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

1740

Start Date

2026-07-20

Completion Date

2033-08-22

Last Updated

2026-07-14

Healthy Volunteers

No

Interventions

DRUG

Efimosfermin alfa

Efimosfermin alfa (subcutaneous injection) will be administered.

DRUG

Placebo

Placebo (subcutaneous injection) will be administered.